Knobbe Martens, Dozens of Partners Receive Top Rankings in IP Law in Legal 500 USA Guide
IRVINE, Calif., June 11, 2026 – Knobbe Martens, a leading intellectual property law firm, is proud to share that the firm and three dozen lawyers received national and regional recognition...
Knobbe Martens Named Among Top Patent Prosecution Leaders in Patexia Report
IRVINE, Calif., April 1, 2026 – Knobbe Martens is pleased to share that the firm and several of its partners were highlighted in Patexia’s 2026 Patent Prosecution Leaders report for...
Life Science Update | December 2025
Purdue Pharma’s $7.4 Billion Chapter 11 Plan Formally Approved Eric Furman, Ph.D. & Rhett D. Ramsey A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11...
Patent Exclusivity and Price Controls: Teva v. Kennedy
On November 20, 2025, the D.C. District Court issued its opinion [1] in a lawsuit where Teva Pharmaceuticals USA, Inc. challenged the validity of the Medicare Drug Price Negotiation Program...
Knobbe Martens Advises Pacira BioSciences in Exclusive License Agreement with AmacaThera for Novel Long-Acting Analgesic
Agreement will support the development and commercialization of non-opioid therapy for postsurgical pain control IRVINE, Calif., November 4, 2025 – A team from Knobbe Martens advised Pacira BioSciences, Inc. in...
Lawdragon Names 17 Knobbe Martens Partners Among ‘Leading Litigators in America’
IRVINE, Calif., September 8, 2025 – Knobbe Martens is pleased to share that 17 of the firm’s partners have been recognized in the 2026 edition of the Lawdragon 500 Leading...
Life Science Update | August 2025
Eyeing the Prize of the U.S. Patent System, the Trump Administration Proposes Patent Maintenance Fee Overhaul Jane Dai, Ph.D. & Susan M. Janicki, Ph.D. The Trump administration is considering changing the U.S....
Eyeing the Prize of the U.S. Patent System, the Trump Administration Proposes Patent Maintenance Fee Overhaul
The Trump administration is considering changing the U.S. patent maintenance fee structure from the existing three fixed flat fees to an annual, value‑based “tax” model where patent holders would pay...
Jane Dai Named a Woman of Influence in Law by San Diego Business Journal
SAN DIEGO, Calif., July 7, 2025 – Knobbe Martens is pleased to announce that partner Jane Dai, Ph.D. has been recognized among the San Diego Business Journal’s Women of Influence in Law. According...
CRISPR Dispute Heats Up With Recent Federal Court Decision
On May 12, 2025, the U.S. Court of Appeals for the Federal Circuit (CAFC) revived the Regents of the University of California’s (Regents) challenge to the Broad Institute’s CRISPR-Cas9 patents,...
Twelve Knobbe Martens Partners Named Among Leading Global IP Lawyers by Lawdragon
IRVINE, Calif., June 2, 2025 – Knobbe Martens is proud to share that 12 of the firm’s partners have been recognized in the inaugural edition of Lawdragon’s “500 Leading Global...
U.S. Supreme Court Defers to Agency Decision-Making in FDA’s Denial of Premarket Approval of Flavored E-Cigarette Products
We previously reported a decision by the U.S. Food and Drug Administration (FDA), denying the premarketing authorization of several flavored e-cigarette product.[1] On April 2, 2025, the Supreme Court of...
Knobbe Martens Advises Pacira BioSciences in Acquisition of Remaining Equity Stake of GQ Bio
SAN DIEGO, Calif., February 28, 2025 – Pacira BioSciences, Inc., the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced...
Nobel Prize in Medicine Awarded to American Scientists for Discovery of microRNA
On October 7, 2024, the 2024 Nobel Prize in Physiology or Medicine was jointly awarded to two American scientists, Victor Ambros (of UMass Medical School) and Gary Ruvkun (of Harvard Medical School), for their discovery of microRNA, a new class of small noncoding RNA molecules, and the role microRNAs play in turning genes on and off, known as gene regulation.
Lawdragon Names Ten Knobbe Martens Partners Among Leading Litigators in America
IRVINE, Calif., September 11, 2024 – Knobbe Martens is pleased to share that ten of the firm’s partners have been recognized in the 2025 edition of Lawdragon’s 500 Leading Litigators...
Sixty Knobbe Martens Attorneys Recognized in “Best Lawyers” 2025 Guide
IRVINE, Calif., August 15, 2024 – Knobbe Martens is pleased to share that Best Lawyers in America has included 60 of the firm’s lawyers in its 2025 Guide. The recognized...
“Improper” Listing of Patents in the FDA’s Orange Book
As we previously discussed, on November 7, 2023, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listings of device patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book” or “OB”).
Knobbe Martens Named a Top Performing Firm, Ten Individuals Ranked Highly for Patent Prosecution in Patexia Report
IRVINE, Calif., March 28, 2024 – Knobbe Martens is proud to announce that the firm and several of its professionals have achieved outstanding rankings in the 2024 Patexia Patent Prosecution...
Antitrust Lawsuit Brought Against Drug Manufacturer Based on Its Allegedly Improper Listing of Device Patents in the FDA’s Orange Book
As we recently discussed recently discussed, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listing of device patents in the Food and Drug Administration’s (“FDA”) Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”). Rahul Rao, the deputy director of the FTC’s Bureau of Competition and the person who signed the warning letters, recently explained the FTC’s position in unequivocal terms: “The Orange Book is only supposed to list patents covering active drug ingredients. So, we focused on device patents that have nothing to do with the active drug.”
The FDA Approves Two New Gene Therapies for the Treatment of Sickle Cell Disease
On December 8, 2023, the U.S. Food and Drug Administration (FDA) approved two new gene therapies for the treatment of sickle cell disease. The first, Casgevy™ (exagamglogene autotemcel (exa-cel)), is the first-ever approved cell-based gene editing therapy to be used in humans, and was developed in joint partnership between Vertex Pharmaceuticals and CRISPR Therapeutics. Casgevy™ is indicated for the treatment of sickle cell disease in patients 12 years and older with recurrent vaso occlusive crises (VOCs). The second, Lyfgenia™ (lovotibeglogene autotemcel (lovo-cel)), is developed by bluebird bio, and is indicated for the treatment of patients 12 years or older with sickle cell disease and a history of vaso-occlusive events (VOEs).
Flavored E-cigarette Manufacturers Face Regulatory Challenges
Manufacturers of e-cigarettes find themselves in a challenging regulatory environment to obtain U.S. Food and Drug Administration (FDA) marketing approval of flavored products. On October 12, 2023, the FDA denied premarket authorization of flavored e-cigarette products from R.J. Reynolds Vapor Company under its Vuse Alto brand. This follows on the heels of the U.S. Supreme Court’s denial of e-cigarette manufacturer Avail Vapor’s challenge to the FDA’s rejection of premarket authorization of Avail Vapor’s flavored e-cigarette products, which was affirmed earlier by the U.S. Court of Appeals for the 4th Circuit. This is the latest case in a series of legal setbacks for the vaping industry, which has ballooned into an $8.2 billion market in less than a decade.
